Last reviewed · How we verify
NCT05099692
CHD Patient's Concern on Cardiac Rehabilitation
trial testing filling out the questionnaire in Coronary Heart Disease in 3,000 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Shenyang Northern Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 15 October 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- filling out the questionnaire
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
- Cardiac Rehabilitation — all drugs for Cardiac Rehabilitation →
Sponsor
Shenyang Northern Hospital
Who can join
18 and older, any sex, with Coronary Heart Disease or Cardiac Rehabilitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our study focuses on the question about primary cardiac rehabilitation (CR) patients with coronary heart disease are concerned about demonstrating the association between the patients' view of CR and social associated factors. In our study, all participants are invited to choose at least 1 question in 15 questions or provide their questions regarding their doubt about the CR after filling in their personal information. The selectable questions can be categorized into five titles: the content or purpose of CR, the method of CR, the advantage of CR, the adverse effect of CR, and the expenditure of CR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05099692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
Other Shenyang Northern Hospital trials
Trials by the same sponsor.
- NCT07445360 — Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary V · NA · not yet recruiting
- NCT07374718 — Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate- · NA · not yet recruiting
- NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
- NCT07362966 — Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant · Phase 4 · not yet recruiting
- NCT07383155 — Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05099692 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Northern Hospital
- Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05099692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing